Literature DB >> 9214409

Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection.

E Sarac1, S Bastacky, J P Johnson.   

Abstract

A 42-year-old man developed mixed cryoglobulinemia secondary to hepatitis C virus (HCV) infection with hypocomplementemia and nephrotic syndrome. His renal biopsy showed membranoproliferative glomerulonephritis type I (MPGN). Despite treatment with interferon-alpha, three million units three times a week for a total of 6 months, the patient continued to have hypocomplementemia, cryoglobulinemia, and nephrosis. After a course of high-dose interferon-alpha treatment consisting of ten million units daily for 2 weeks followed by 10 million units three times per week for an additional 6 weeks, HCV RNA and cryoglobulin testing became negative, complement levels increased to normal levels, and nephrotic syndrome remitted. This case confirms an association between HCV infection and MPGN and suggests a role for high-dose interferon-alpha treatment when conventional interferon therapy fails.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9214409     DOI: 10.1016/s0272-6386(97)90572-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.

Authors:  I H Y Cua; V Kwan; M Henriquez; J Kench; J George
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation.

Authors:  Marilyn Zeman; Patricia Campbell; Vincent G Bain
Journal:  Can J Gastroenterol       Date:  2006-06       Impact factor: 3.522

Review 3.  Kidney disease in patients with chronic hepatitis C.

Authors:  M Philipneri; B Bastani
Journal:  Curr Gastroenterol Rep       Date:  2001-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.